Eli Lilly will invest $6B in a new Huntsville plant to scale production of its experimental obesity pill and other drugs, part of a broader U.S. manufacturing build-out driven by supply-chain and tariff concerns. Construction begins in 2026 and runs through 2032, adding thousands of jobs.
